Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00993148 | Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1 | PHASE2 | COMPLETED | 25 | — | — | May 1, 2010 | Apr 1, 2013 | Sep 5, 2014 | 5 | United States |
Percentage of participants with confirmed plasma HIV-1 RNA \> 50 copies/mL
| Arm | Type | Description |
|---|---|---|
| Maraviroc plus darunavir/ritonavir | EXPERIMENTAL | Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks |
| Name | Type | Description |
|---|---|---|
| maraviroc | DRUG | 150 mg tab by mouth once daily for 96 weeks |
| darunavir | DRUG | 800 mg tab by mouth once daily for 96 weeks |
| ritonavir | DRUG | 100 mg capsule by mouth once daily for 96 weeks |
Inclusion Criteria: * HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA any time prior to study entry * Plasma HIV-1 RNA 5, 000 to 500,000 copies/mL obtain...